Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NTLA | Common Stock | Options Exercise | +3.5K | +142.1% | 5.96K | Jan 1, 2022 | Direct | F1, F2 | ||
transaction | NTLA | Common Stock | Sale | -$129K | -1.15K | -19.25% | $112.25 | 4.82K | Jan 1, 2022 | Direct | F3 |
transaction | NTLA | Common Stock | Award | $0 | +13.8K | +286.94% | $0.00 | 18.6K | Mar 1, 2022 | Direct | F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NTLA | Restricted Stock Unit | Options Exercise | $0 | -3.5K | -25% | $0.00 | 10.5K | Jan 1, 2022 | Common Stock | 3.5K | Direct | F1, F5 | |
transaction | NTLA | Stock Option (right to buy) | Award | $0 | +13.8K | $0.00 | 13.8K | Mar 1, 2022 | Common Stock | 13.8K | $79.85 | Direct | F6 |
Id | Content |
---|---|
F1 | Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
F2 | Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021. |
F3 | Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022. |
F4 | Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
F5 | On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. |
F6 | This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |